Nab-sirolimus is named as a drug or biological intervention in 3 clinical trials in our USA trial register, 2 of which are recruiting. The lead sponsor is Aadi Bioscience, Inc.. Registered phases: Phase 2 and Phase 1. Conditions studied include Tumor; Tumor, Solid; Advanced Solid Tumor.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05997017 | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer (ClinicalTrials.gov ↗) Endometrial Cancer, Endometrioid Tumor, Cancer |
Phase 2 | Recruiting |
| NCT05661461 | Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment Tumor, Solid, Tumor, Advanced Solid Tumor |
Phase 1 | Recruiting |
| NCT05103358 | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (ClinicalTrials.gov ↗) Tumor, Tumor, Solid, Metastasis |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Tumor | 3 |
| Tumor, Solid | 2 |
| Advanced Solid Tumor | 1 |
| Endometrial Cancer | 1 |
| Endometrioid Tumor | 1 |
| Cancer | 1 |
| Metastasis | 1 |
| Metastatic Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Aadi Bioscience, Inc. | 3 |
| Register | Nab-sirolimus trials |
|---|---|
| Clinical trials in USA | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nab-sirolimus works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nab-sirolimus (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.